Avantor (AVTR) Projected to Post Quarterly Earnings on Friday

Avantor (NYSE:AVTRGet Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Friday, April 25th. Analysts expect Avantor to post earnings of $0.23 per share and revenue of $1.61 billion for the quarter.

Avantor (NYSE:AVTRGet Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Avantor had a return on equity of 12.17% and a net margin of 10.49%. During the same quarter last year, the business earned $0.22 EPS. On average, analysts expect Avantor to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Avantor Price Performance

Shares of NYSE:AVTR opened at $15.30 on Wednesday. The stock’s 50 day moving average price is $16.20 and its 200 day moving average price is $19.97. The stock has a market cap of $10.43 billion, a price-to-earnings ratio of 14.71, a PEG ratio of 1.55 and a beta of 1.24. Avantor has a 12 month low of $13.80 and a 12 month high of $28.00. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.07 and a quick ratio of 0.70.

Insiders Place Their Bets

In related news, CAO Steven W. Eck sold 4,907 shares of the firm’s stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $17.53, for a total value of $86,019.71. Following the completion of the transaction, the chief accounting officer now owns 40,604 shares of the company’s stock, valued at approximately $711,788.12. This trade represents a 10.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP James Bramwell sold 3,758 shares of the firm’s stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $17.53, for a total transaction of $65,877.74. Following the completion of the transaction, the executive vice president now directly owns 87,379 shares of the company’s stock, valued at $1,531,753.87. This represents a 4.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on AVTR. Wells Fargo & Company cut their target price on shares of Avantor from $25.00 to $22.00 and set an “overweight” rating for the company in a research note on Thursday, April 17th. Stifel Nicolaus dropped their price target on shares of Avantor from $28.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday, February 10th. Barclays cut their price target on Avantor from $23.00 to $18.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. UBS Group reissued a “neutral” rating and set a $25.00 price objective (down from $29.00) on shares of Avantor in a report on Friday, January 17th. Finally, Citigroup decreased their price objective on shares of Avantor from $22.00 to $18.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, Avantor presently has a consensus rating of “Moderate Buy” and an average target price of $24.82.

Get Our Latest Research Report on Avantor

Avantor Company Profile

(Get Free Report)

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.

Read More

Earnings History for Avantor (NYSE:AVTR)

Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.